Clinical trialNCT06262282Enrolling, by, invitationObservational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

SponsorNational Jewish HealthEnrollment10Cystic FibrosisMycobacterium InfectionsMycobacterium; PulmonaryNontuberculous Mycobacterial Lung DiseaseNontuberculous Mycobacterium Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in killing the mycobacteria. Individuals who are found to have at least one phage will be offered assistance in pursuing FDA approval for treatment via expanded-access Individual New Drug (IND) for compassionate-use. They will receive phage treatment for 1 year along with their guideline-based antibiotics for NTM. Individuals who are not identified as having a phage match will be followed as they continue to receive guideline based antibiotic therapy for 1 year. All subjects, including those who do not have a phage match will continue to be observed for the duration of the study, or about 1 year.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jerry Nick, MD
National Jewish Health
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama
Birmingham, Alabama, United States
Children'S Hospital of Los Angeles
Los Angeles, California, United States
University of California
San Diego, California, United States
Childrens Hospital Colorado
Denver, Colorado, United States
National Jewish Health
Denver, Colorado, United States
University of Florida
Gainesville, Florida, United States
Northwestern University
Chicago, Illinois, United States
John Hopkins University
Baltimore, Maryland, United States
Boston Childrens Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Columbia University
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Southwestern Medical Center at Dallas
Dallas, Texas, United States
University of Vermont
Burlington, Vermont, United States
University of Washington
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mycobacteriophage

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Feb 2024
Primary completion: 31 Dec 2026
Completion: 31 Dec 2028
Last update posted: 21 May 2025
Registered enrollment: 10
Registry id: NCT06262282

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.